These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28170382)

  • 1. The double edge of cancer immunotherapy.
    Nat Med; 2017 Feb; 23(2):137. PubMed ID: 28170382
    [No Abstract]   [Full Text] [Related]  

  • 2. The struggle to do no harm in clinical trials.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235
    [No Abstract]   [Full Text] [Related]  

  • 3. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial overview: Cancer Immunotherapy: Are we there yet?
    Ohashi PS; Sharpe A
    Curr Opin Immunol; 2021 Apr; 69():iii-v. PubMed ID: 33985756
    [No Abstract]   [Full Text] [Related]  

  • 5. Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition.
    Dein E; Sharfman W; Kim J; Gellad F; Shah AA; Bingham CO; Cappelli LC
    J Immunother; 2017 Oct; 40(8):312-314. PubMed ID: 28614096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
    J Immunother; 2017 Jun; 40(5):196-199. PubMed ID: 28452849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
    Denis M; Duruisseaux M; Brevet M; Dumontet C
    Front Immunol; 2020; 11():492. PubMed ID: 32265935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view].
    Cisarovsky C; Kraege V; Obeid M; Garnier A
    Rev Med Suisse; 2020 Nov; 16(716):2264-2270. PubMed ID: 33237644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
    Pourmir I; Nebbache R; Champiat S; Lambotte O;
    Ann Oncol; 2024 Jun; 35(6):569-570. PubMed ID: 38548063
    [No Abstract]   [Full Text] [Related]  

  • 12. Adapting Cancer Immunotherapy Models for the Real World.
    Klevorn LE; Teague RM
    Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy-Related Adverse Effects When Treating Cancer #375.
    Matts C; Beck A
    J Palliat Med; 2019 Jun; 22(6):724-725. PubMed ID: 31158056
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care.
    Klionsky Y; Simon Meara A; Reid P
    Rheum Dis Clin North Am; 2024 May; 50(2):229-239. PubMed ID: 38670722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
    Ng CY; Chen CB; Wu MY; Wu J; Yang CH; Hui RC; Chang YC; Lu CW
    J Immunol Res; 2018; 2018():5376476. PubMed ID: 29577050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experts To Address Rare, Toxic Downside of Immunotherapy.
    Jenks S
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053210
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician.
    Lomax AJ; McNeil C
    Emerg Med Australas; 2017 Apr; 29(2):245-251. PubMed ID: 28093870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    Zecchini JM; Kim S; Yum K; Friedlander P
    J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.